Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 249-955-7 | CAS number: 29920-31-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2021
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 021
- Report date:
- 2021
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- in vitro mammalian chromosome aberration test
Test material
- Reference substance name:
- Dimethyl 2-[[1-[[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)amino]carbonyl]-2-oxopropyl]azo]terephthalate
- EC Number:
- 252-650-1
- EC Name:
- Dimethyl 2-[[1-[[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)amino]carbonyl]-2-oxopropyl]azo]terephthalate
- Cas Number:
- 35636-63-6
- Molecular formula:
- C21H19N5O7
- IUPAC Name:
- dimethyl 2-({2-oxo-1-[(2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)carbamoyl]propyl}diazenyl)terephthalate
- Test material form:
- solid: nanoform
Constituent 1
Method
Species / strain
- Species / strain / cell type:
- Chinese hamster Ovary (CHO)
- Cytokinesis block (if used):
- Colchicine was used as the spindle inhibitor at 0.2 μg/mL
- Metabolic activation:
- with and without
- Metabolic activation system:
- Aroclor 1254-induced rat liver S9 homogenate was used as the metabolic activation system. The S9 homogenate was prepared from male Wistar rats induced with a single intraperitoneal injection of Aroclor 1254 (0.7 mL/rat ready to use solution), 5 days prior to sacrifice.
The S9 homogenate batch prepared and stored in the test facility either at -68 to -86 °C or in liquid
nitrogen until its use. Each batch of S9 homogenate is assessed for sterility, protein content (modified Lowry Assay, Sword and Thomson, 1980) and for its ability to metabolize the pro-mutagens 2-Aminoanthracene and Benzo (a) pyrene to mutagens using Salmonella typhimurium TA100 strain.
S9 homogenate was thawed immediately before use and mixed with the co-factor solution containing 4 mM NADP, 5 mM Glucose-6-phosphate, 8 mM MgCl2 and 33 mM KCl in PBS.
7.2.1 S9 Mix
The co-factor solution was prepared by dissolving the following co-factors in 18 mL PBS for the preliminary cytotoxicity test and the chromosome aberration assay.
NADP (4 mM) 57 mg
Glucose-6-phosphate (5 mM) 31 mg
Magnesium chloride (8 mM) 29 mg
Potassium chloride (33 mM) 44 mg
The S9 mix was prepared by mixing 4 mL S9 homogenate with 16 mL of the co-factor solution, for the preliminary cytotoxicity test and the chromosomal aberration assay. - Test concentrations with justification for top dose:
Test Concentrations
Following concentrations of the test item were used in the preliminary cytotoxicity test:
a) 7.81, b) 15.63, c) 31.25, d) 62.5, e) 125, f) 250, g) 500, h) 1000 and i) 2000 μg/mL (limit concentration as per OECD 473).
At the beginning and end of 3-hour exposure period, there was no precipitation of the test item, both in the presence and absence of metabolic activation at the test concentrations of 7.81, 15.63, 31.25, 62.5 and 125 µg/mL.
At the beginning and end of the 3-hour exposure, both in the presence and absence of metabolic activation, there was slight precipitation of the test item at 250 µg/mL and moderate precipitation of the test item at 500, 1000 and 2000 µg/mL.
Based on the guideline requirement, the test concentrations which exhibited moderate precipitation of the test item were not processed further and 250 µg/mL, which exhibited slight precipitation of the test item was selected as the top concentration in the preliminary cytotoxicity test.
Based on observations and preliminary cytotoxicity test results, it was decided to test up to a maximum of 250 µg/mL in the presence and absence of metabolic activation with the 3-hour exposure and in the absence of metabolic activation with the 21-hours exposure period in the chromosomal aberration assay.
Main test
Based on the observations of the preliminary cytotoxicity test, following concentrations of the test item are selected for testing in the chromosomal aberration assay
a) 15.63 b) 62.5 and c) 250 μg/mL- Vehicle / solvent:
- Sterile water
Controls
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- ethylmethanesulphonate
- Details on test system and experimental conditions:
- Chinese Hamster (Cricetulus griseus) ovary cell line CHO-K1, (ATCC CCL-61, Lot 63830396) with a doubling time approximately 12 -14 hours and modal chromosome number of 20 was used as the test system.
The cell line was tested for mycoplasma in the testing facility. The karyotype analysis of this cell line was periodically performed and documented.
Cells were grown in T- 25 cm2 and T-75 cm2 flasks at 37 ± 1 °C in a carbon dioxide incubator (5 ± 0.2 % CO2 in air)
The study consisted of a preliminary cytotoxicity test and a chromosome aberration assay. Chromosome aberration assay consisted of three independent experiments: Experiments 1 and 2 in the presence and absence of metabolic
activation system with 3-hour exposure, respectively, and Experiment 3 in the absence of metabolic activation system with 21-hour exposure.
The test item formed a free flowing suspension in sterile water at 200 mg/mL and a pasty suspension in DMSO at 200 mg/mL. Hence, sterile water was selected as the vehicle of choice for the chromosomal aberration test.
In a preliminary cytotoxicity test for the selection of test concentrations for the chromosomal aberration assay, the test item did not exhibit the required level of cytotoxicity (reduction in the cell growth by 55 ± 5 % of the concurrent vehicle control) up to the highest tested concentration of 250 μg/mL, both, in the presence and absence of metabolic activation (short term treatment) and in the absence of metabolic activation (long term treatment).
Based on these observations and preliminary cytotoxicity test results, it was decided to test up to a maximum of 250 μg/mL in the presence and absence of metabolic activation with the 3-hour exposure and in the absence of metabolic activation with the 21-hours exposure period in the chromosomal aberration assay.
In the chromosomal aberration assay, CHO-K1 cells were exposed to the test item in duplicate at the concentrations of 15.63, 62.5 and 250 μg/mL in Experiments 1, 2 and 3 of the chromosomal aberration assay. Concurrent vehicle (SW) and positive controls (cyclophosphamide monohydrate in the presence of metabolic activation and ethyl methanesulfonate in the absence of metabolic activation at 21 hour exposure) were also tested in duplicate. In each case, the cells in C-metaphase were harvested at approximately 21 hours after the start of the treatment and slides were prepared for chromosomal analysis.
At the highest concentrations tested, the reduction in cell growth as RICC was 47, 43 and 53 % in experiments 1, 2 and 3, respectively, compared to the vehicle control.
A total of 300 metaphases each from the SW control, each treatment level and the positive controls were evaluated for chromosomal aberrations. - Rationale for test conditions:
- Conditions according to guideline
- Evaluation criteria:
- Metaphases of all concentrations of the test item, the positive and vehicle control cultures were scored.
8.1 Definition for Aberrations
The chromosome and chromatid aberrations observed have been grouped into three categories - gaps, breaks (includes deletions and displacements) and exchanges.
Gap
Chromatid gap is a non-staining region of a single chromatid in which there is a minimal misalignment of the chromatid.
Chromosome gap is a non-staining region at the same locus in both chromatids of a single chromosome in which there is minimal misalignment of the chromatids.
Break
Chromatid break is discontinuity of a single chromatid in which there is clear misalignment of one of the chromatids.
Chromosome break is discontinuity at the same locus in both chromatids of a single chromosome, giving rise to an acentric fragment.
A chromatid deletion occurs when a bit of chromatid is missing as a result of a break.
A chromosome deletion occurs when bits of both chromatids are missing as a result of a break.
Chromatid displacement occurs when the fragment of the chromatid beyond the break point is not in alignment with the chromosome of origin.
Chromosome displacement occurs when the fragments of both chromatids beyond the break point are not in alignment with the chromosome of origin.
Exchange
Exchanges occur as a result of two or more chromatid lesions and the subsequent rearrangement of chromatid material.
Ring chromosomes are formed when a chromosome undergoes two breaks and the broken ends of the chromosome reunite in a ring structure either with or without a centromere.
Pulverization
In cells with pulverization, the chromosomes are reduced to masses of fragments. This represents the degree of damage inflicted on the chromosome. This aberration indicates the cytotoxic effect of the test item.
Polyploidy
Cell containing more than the diploid number (2n) of chromosomes, - Statistics:
- Statistical analysis of the experimental data was carried out using validated SYSTAT Statistical package ver.12.0. Data were analyzed for proportions of aberrant metaphases in each sample excluding gaps as aberrations. Pooled data from each test concentration and the positive control were compared with the vehicle control using Fischer exact test. All analysis and comparisons were evaluated at 5 % (p < 0.05) level.
Results and discussion
Test results
- Key result
- Species / strain:
- Chinese hamster Ovary (CHO)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity, but tested up to precipitating concentrations
- Vehicle controls validity:
- valid
- Positive controls validity:
- valid
Any other information on results incl. tables
TABLE 3. Results of Preliminary Cytotoxicity Test
Treatment (µg/mL) | Presence of metabolic activation (3-hour exposure) | Absence of metabolic activation (3-hour exposure) | Absence of metabolic activation (21-hour exposure) | ||||||
Final – initial cell count (1x106/flask) | Cell growth index RICC (%) | Cell growth inhibition (%) | Final – initial cell count (1x106/flask) | Cell growth index RICC (%) | Cell growth inhibition (%) | Final – initial cell count (1x106/flask) | Cell growth index RICC (%) | Cell growth inhibition (%) | |
Sterile water | 0.78125 | 100 | 0 | 0.83125 | 100 | 0 | 0.71875 | 100 | 0 |
7.81 | 0.71875 | 92 | 8 | 0.79375 | 95 | 5 | 0.63125 | 88 | 12 |
15.63 | 0.63125 | 81 | 19 | 0.73125 | 88 | 12 | 0.55625 | 77 | 23 |
31.25 | 0.56875 | 73 | 27 | 0.68125 | 82 | 18 | 0.50625 | 70 | 30 |
62.5 | 0.51875 | 66 | 34 | 0.60625 | 73 | 27 | 0.43125 | 60 | 40 |
125 | 0.48125 | 62 | 38 | 0.55625 | 67 | 33 | 0.38125 | 53 | 47 |
250 | 0.41875 | 54 | 46 | 0.49375 | 59 | 41 | 0.31875 | 44 | 56 |
Base line cell count: 1.58125 X 106/flask
TABLE 4. Summary Results of Chromosomal Aberration Assay - Experiment 1
Treatment (µg/mL) | No. of metaphases scored | No. (%) of metaphases with aberrations@ | Total No. (%) of aberrant metaphases* | Cell Growth Inhibition (%) | ||||||
Gaps | Breaks | Exchanges | Includi ng Gaps | Excluding Gaps | ||||||
Cs | Ct | Cs | Ct | Cs | Ct | |||||
Sterile water | 300 |
0 |
0 |
1 (0.33) |
0 |
0
|
0 |
1 (0.33) |
1 (0.33) | 0 |
15.63 | 300 |
0
|
0 |
0 |
0 |
0 |
0 |
0 |
0 | 16 |
62.5 | 300 |
0
|
0 |
0 |
0 |
0 |
0 |
0 |
0 | 33 |
250 | 300 |
0 |
0 |
1 (0.33) |
0 |
0 |
0 |
1 (0.33) |
1 (0.33) | 47 |
CPA 55 | 300 |
1 (0.33) |
0 |
12 (4.00) |
19 (6.33) |
38 (12.67) |
31 (10.33) |
73 (24.33) |
72+ (24.00) | 35 |
*: Metaphase plate with one or more than one aberration considered as one metaphase plate with aberrations
@: values are the sum of two replicates and values in parenthesis represent %
Cs: Chromosome type Ct: Chromatid type
CPA: Cyclophosphamide monohydrate +: Significantly higher than control (p <0.05) by Fischer exact test Note: There were no incidences of polyploidy and endoreduplicated cells
TABLE 5. Summary Results of Chromosomal Aberration Assay - Experiment 2
Treatment (µg/mL) | No. of metaphases scored | No. (%) of metaphases with aberrations@ | Total No. (%) of aberrant metaphases* | Cell Growth Inhibition (%) | ||||||
Gaps | Breaks | Exchanges | Including Gaps | Excluding Gaps | ||||||
Cs | Ct | Cs | Ct | Cs | Ct | |||||
Sterile water | 300 |
1 (0.33) | 0 | 0 | 0 | 0 | 0 |
1 (0.33) | 0 | 0 |
15.63 | 300 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
10 |
62.5 | 300 | 0 |
1 (0.33) | 0 | 0 | 0 | 0 |
1 (0.33) | 0 |
25 |
250 | 300 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
43 |
*: Metaphase plate with one or more than one aberration considered as one metaphase plate with aberrations
@: values are the sum of two replicates and values in parenthesis represent %
Cs: Chromosome type Ct: Chromatid type
Note: There were no incidences of polyploidy and endoreduplicated cells
TABLE 6. Summary Results of Chromosomal Aberration Assay - Experiment 3
Treatment (µg/mL) | No. of metaphases scored | No. (%) of metaphases with aberrations@ | Total No. (%) of aberrant metaphases* | Cell Growth Inhibition (%) | ||||||
Gaps | Breaks | Exchanges | Including Gaps | Excluding Gaps | ||||||
Cs | Ct | Cs | Ct | Cs | Ct | |||||
Sterile water | 300 | 0 | 0 |
1 (0.33) | 0 | 0 | 0 |
1 (0.33) |
1 (0.33) | 0 |
15.63 | 300 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22 |
62.5 | 300 | 0 | 0 |
0 |
1 (0.33) | 0 | 0 |
1 (0.33) |
1 (0.33) | 38 |
250 | 300 | 0 | 0 |
1 (0.33) | 0 | 0 | 0 |
1 (0.33) |
1 (0.33) | 53 |
EMS 600 | 300 |
4 (1.33) | 0 |
35 (11.67) |
36 (12.00) |
9 (3.00) |
15 (5.00) |
84 (28.00) |
81+ (27.00) | 28 |
*: Metaphase plate with one or more than one aberration considered as one metaphase plate with aberrations
@: values are the sum of two replicates and values in parenthesis represent %
Cs: Chromosome type Ct: Chromatid type
EMS: Ethyl methanesulfonate +: Significantly higher than control (p <0.05) by Fischer exact test
Note: There were no incidences of polyploidy and endoreduplicated cells
ANNEXURE 2. Historical Vehicle and Positive Control Data
Test System: CHO cells No. of Studies: 56
Vehicle Control
Parameter | Total No. of Metaphases with Aberrations Excluding Gaps | |
Presence of Metabolic Activation | Absence of Metabolic Activation | |
Range | 0 - 5 | 0 - 4 |
Mean ± SD | 0 ± 1 | 1 ± 1 |
Positive Control
Parameter | Total No. of Metaphases with Aberrations Excluding Gaps | |
Presence of Metabolic Activation | Absence of Metabolic Activation | |
Range | 51 - 204 | 63 - 248 |
Mean ± SD | 124 ± 37 | 121 ± 32 |
CHO: Chinese Hamster Ovary Cells
SD: Standard deviation
Applicant's summary and conclusion
- Conclusions:
- The test item, C.I. Pigment Yellow 175 was not clastogenic in CHO-K1 cells at the tested concentration and under the conditions of testing employed.
- Executive summary:
The clastogenic potential of the test item, C.I. Pigment Yellow 175 to induce chromosomal aberrations in mammalian cells was evaluated using cultured Chinese Hamster Ovary (CHO-K1) cells in the presence and absence of an exogenous metabolic activation system (S9 fraction prepared from Aroclor 1254 induced rat liver).
The study consisted of a preliminary cytotoxicity test and a chromosome aberration assay. Chromosome aberration assay consisted of three independent experiments: Experiments 1 and 2 in the presence and absence of metabolic activation system with 3-hour exposure, respectively, and Experiment 3 in the absence of metabolic activation system with 21-hour exposure.
The test item formed a free flowing suspension in sterile water at 200 mg/mL and a pasty suspension in DMSO at 200 mg/mL. Hence, sterile water was selected as the vehicle of choice for the chromosomal aberration test.
In a preliminary cytotoxicity test for the selection of test concentrations for the chromosomal aberration assay, the test item did not exhibit the required level of cytotoxicity (reduction in the cell growth by 55± 5 % of the concurrent vehicle control)up to the highest tested concentration of 250µg/mL,both, in the presence and absence of metabolic activation (short term treatment) and in the absence of metabolic activation (long term treatment).
Based on these observations and preliminary cytotoxicity test results, it was decided to test up to a maximum of 250 µg/mL in thepresence and absence of metabolic activation with the 3-hour exposure and in the absence of metabolic activation with the 21-hours exposure period in the chromosomal aberration assay.
In the chromosomal aberration assay, CHO-K1 cells were exposed to the test item in duplicate at the concentrations of 15.63, 62.5 and 250mg/mL in Experiments 1, 2 and 3 of the chromosomal aberration assay. Concurrent vehicle (SW) and positive controls (cyclophosphamide monohydrate in the presence of metabolic activation and ethyl methanesulfonate in the absence of metabolic activation at 21 hour exposure) were also tested in duplicate. In each case, the cells in C-metaphase were harvested at approximately 21 hours after the start of the treatment and slides were prepared for chromosomal analysis.
At the highest concentrations tested, the reduction in cell growth as RICC was 47, 43 and 53 % in experiments 1, 2 and 3, respectively, compared to the vehicle control.
A total of 300 metaphases each from the SW control, each treatment level and the positive controls were evaluated for chromosomal aberrations.
There was no evidence of statistically significant induction of chromosomal aberrations, excluding gaps, either in the presence or in the absence of metabolic activation. In each of these experiments, under identical conditions, the respective positive control substances produced a large and statistically significant increase in aberrant metaphases.
The study indicated that the test item, C.I. Pigment Yellow 175 was not clastogenic at the concentrations tested and under the conditions of testing
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)